Logo

IBIO

iBio, Inc.

IBIO

iBio, Inc. • NASDAQ
$1.23 ▲ 2.50% (+0.03)
Market Cap $20.33 M
52w High $6.89
52w Low $0.56
Dividend Yield 0%
P/E -0.88
Volume 342.53K
Outstanding Shares 16.53M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $100K ▼ $5.762M ▲ $-5.72M ▼ -5.72K% ▼ $-0.11 ▲ $-5.395M ▼
Q4-2025 $200K ▲ $5.398M ▲ $-5.163M ▼ -2.582K% ▼ $-0.31 ▲ $-4.834M ▼
Q3-2025 $0 ▼ $4.879M ▲ $-4.861M ▼ 0% ▲ $-0.49 ▼ $-4.525M ▼
Q2-2025 $200K ▲ $4.619M ▲ $-4.364M ▼ -2.182K% ▼ $-0.48 ▼ $-4.026M ▼
Q1-2025 $0 $4.106M $-3.989M 0% $-0.46 $-3.654M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $49.567M ▲ $64.155M ▲ $8.116M ▼ $56.039M ▲
Q4-2025 $8.582M ▲ $23.185M ▲ $8.305M ▲ $14.88M ▲
Q3-2025 $4.959M ▼ $19.103M ▼ $7.722M ▼ $11.381M ▼
Q2-2025 $7.015M ▼ $21.697M ▼ $7.802M ▲ $13.895M ▼
Q1-2025 $11.038M $24.517M $6.763M $17.754M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-5.72M ▼ $-5.665M ▼ $-21.493M ▼ $46.705M ▲ $19.529M ▲ $-5.697M ▼
Q4-2025 $-5.163M ▼ $-4.615M ▼ $45K ▲ $8.18M ▲ $3.61M ▲ $-4.616M ▼
Q3-2025 $-4.861M ▼ $-3.105M ▲ $-14K ▼ $1.063M ▲ $-2.056M ▲ $-3.119M ▲
Q2-2025 $-4.364M ▼ $-3.869M ▼ $-2K ▼ $-152K ▲ $-4.023M ▼ $-3.87M ▼
Q1-2025 $-3.989M $-3.715M $713K $-162K $-3.164M $-3.715M

Revenue by Products

Product Q4-2021Q1-2022Q2-2022Q3-2022
Ibio Cdmo
Ibio Cdmo
 $0 ▲$0 ▲$0 ▲$0 ▲
Ibio Inc
Ibio Inc
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement iBio looks like a classic early‑stage biotech: it has essentially no product revenue and runs the business as a research platform. The income statement is dominated by ongoing operating losses tied to R&D and overhead. Losses have been steady over several years, and per‑share figures are heavily distorted by repeated reverse stock splits, so headline earnings per share swings say more about capital structure changes than about business performance. Profitability depends entirely on future success in moving drug candidates into the clinic and securing partnerships or licensing deals.

Balance Sheet

Balance Sheet The balance sheet is very small and has been shrinking over time. Cash makes up a large share of total assets, but the overall cash pool is modest and has edged down as the company funds operations. On the positive side, interest‑bearing debt has recently been reduced to essentially zero, lowering financial risk from lenders. However, shareholders’ equity is thin, suggesting limited cushion against setbacks and a high likelihood that future funding would need to come from issuing more shares or deals with partners. Overall financial flexibility appears constrained for a long, capital‑intensive drug development journey.

Cash Flow

Cash Flow Cash flows show a pattern typical of pre‑revenue biotech: steady cash outflows from operating activities, driven mainly by research spending and corporate costs, with no offsetting inflows from product sales. Investment in equipment and facilities is relatively light, so most cash burn is operational rather than capital‑intensive. Free cash flow is consistently negative, meaning the company depends on external financing—equity offerings, partnerships, or other instruments—to keep advancing its pipeline. This creates ongoing funding risk and sensitivity to market conditions.

Competitive Edge

Competitive Edge Competitively, iBio is trying to stand out with an AI‑driven antibody discovery platform focused on precise targeting of disease‑related proteins. Its epitope‑engineering approach, human antibody library, and specialized tools for T‑cell engagers and masked antibodies give it a differentiated technical story. At the same time, it operates in a fiercely competitive space that includes large pharmaceutical firms and well‑funded AI‑biotech peers. iBio lacks commercial products, scale, and a long track record, so its competitive position will be determined by whether it can generate compelling preclinical and early clinical data and convert that into strong partnerships.

Innovation and R&D

Innovation and R&D Innovation and R&D are the heart of iBio. The company is betting on a suite of proprietary tools—AI‑based epitope selection, antibody optimization, and conditional activation technologies—to design “smarter” antibodies. Its pipeline targets two hot areas: obesity and cardiometabolic diseases, where it aims to improve weight loss quality and muscle preservation, and immuno‑oncology, where it is developing next‑generation antibodies and T‑cell engagers. However, the programs are still preclinical, so there is substantial scientific, regulatory, and timing uncertainty. Progress will likely be marked by preclinical milestones, regulatory filings, and any transition into human trials over the next several years.

Summary

Overall, iBio is a very early‑stage biotech with an ambitious technology platform but a small and resource‑constrained financial base. The company is pre‑revenue, runs persistent losses, and consumes cash each year, relying on external funding to move forward. On the strategic side, it is focused and specialized: AI‑enabled antibody discovery in high‑value disease areas, with multiple novel candidates in the lab. The main opportunities lie in converting this innovation into clinical‑stage assets and partnerships with larger players. The main risks center on financing needs, the long and uncertain path of drug development, intense competition, and the limited buffer provided by its current balance sheet.

NEWS

November 24, 2025 · 4:15 PM UTC

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Read more

November 12, 2025 · 4:01 PM UTC

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Read more

October 30, 2025 · 7:00 AM UTC

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Read more

October 23, 2025 · 7:00 AM UTC

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Read more

October 21, 2025 · 7:00 AM UTC

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Read more